Gaerolwe Masheto, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Postpartum Period | 6 | 2024 | 1198 | 0.840 |
Why?
|
HIV Infections | 20 | 2024 | 17591 | 0.810 |
Why?
|
Anti-HIV Agents | 8 | 2024 | 4576 | 0.680 |
Why?
|
Isoniazid | 8 | 2024 | 288 | 0.670 |
Why?
|
Tuberculosis | 7 | 2024 | 2029 | 0.490 |
Why?
|
Vascular Diseases | 1 | 2023 | 1163 | 0.470 |
Why?
|
Bone Density | 1 | 2024 | 3574 | 0.370 |
Why?
|
Antitubercular Agents | 6 | 2024 | 1397 | 0.360 |
Why?
|
Pregnancy Complications, Infectious | 5 | 2024 | 2190 | 0.330 |
Why?
|
Stillbirth | 2 | 2023 | 381 | 0.290 |
Why?
|
Latent Tuberculosis | 2 | 2021 | 224 | 0.290 |
Why?
|
Abortion, Spontaneous | 2 | 2024 | 535 | 0.270 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2019 | 664 | 0.250 |
Why?
|
Pregnancy Outcome | 5 | 2024 | 2974 | 0.240 |
Why?
|
Colposcopy | 1 | 2024 | 151 | 0.220 |
Why?
|
Pregnancy | 14 | 2024 | 30265 | 0.220 |
Why?
|
Benzoxazines | 2 | 2023 | 321 | 0.200 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2023 | 296 | 0.200 |
Why?
|
E-Selectin | 1 | 2023 | 578 | 0.180 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2023 | 692 | 0.170 |
Why?
|
Botswana | 1 | 2023 | 1065 | 0.170 |
Why?
|
Alkynes | 1 | 2020 | 327 | 0.170 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2023 | 1133 | 0.160 |
Why?
|
Cyclopropanes | 1 | 2020 | 437 | 0.160 |
Why?
|
Adenine | 2 | 2023 | 995 | 0.160 |
Why?
|
Oxazines | 1 | 2021 | 358 | 0.160 |
Why?
|
Creatinine | 1 | 2024 | 1917 | 0.160 |
Why?
|
Absorptiometry, Photon | 1 | 2024 | 1758 | 0.150 |
Why?
|
CD4 Lymphocyte Count | 3 | 2019 | 2598 | 0.140 |
Why?
|
Nystatin | 1 | 2017 | 22 | 0.140 |
Why?
|
Gentian Violet | 1 | 2017 | 25 | 0.140 |
Why?
|
Candidiasis, Oral | 1 | 2017 | 57 | 0.140 |
Why?
|
Rifampin | 1 | 2019 | 351 | 0.140 |
Why?
|
Viremia | 1 | 2020 | 725 | 0.140 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2021 | 1360 | 0.130 |
Why?
|
Pyridones | 1 | 2021 | 819 | 0.130 |
Why?
|
Birth Weight | 1 | 2023 | 2121 | 0.120 |
Why?
|
Premature Birth | 2 | 2024 | 1830 | 0.110 |
Why?
|
Placenta | 1 | 2023 | 1725 | 0.110 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1640 | 0.100 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2024 | 2044 | 0.100 |
Why?
|
Antifungal Agents | 1 | 2017 | 761 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2019 | 1903 | 0.090 |
Why?
|
Mycobacterium tuberculosis | 1 | 2021 | 1930 | 0.090 |
Why?
|
Piperazines | 1 | 2021 | 2553 | 0.090 |
Why?
|
Infant | 5 | 2024 | 36556 | 0.090 |
Why?
|
Female | 19 | 2024 | 397515 | 0.080 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 1795 | 0.080 |
Why?
|
Mothers | 1 | 2019 | 2209 | 0.080 |
Why?
|
Viral Load | 3 | 2023 | 3398 | 0.070 |
Why?
|
Young Adult | 7 | 2024 | 60131 | 0.070 |
Why?
|
Adult | 12 | 2024 | 223851 | 0.060 |
Why?
|
HIV-1 | 1 | 2023 | 6962 | 0.060 |
Why?
|
HIV | 2 | 2024 | 1597 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2019 | 3235 | 0.060 |
Why?
|
Humans | 20 | 2024 | 768970 | 0.060 |
Why?
|
Tablets | 1 | 2023 | 149 | 0.050 |
Why?
|
Dideoxynucleosides | 1 | 2023 | 135 | 0.050 |
Why?
|
Lamivudine | 1 | 2023 | 367 | 0.050 |
Why?
|
Infant, Newborn | 4 | 2024 | 26428 | 0.050 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2024 | 392 | 0.050 |
Why?
|
Tuberculin Test | 1 | 2021 | 205 | 0.050 |
Why?
|
Cervix Uteri | 1 | 2024 | 577 | 0.050 |
Why?
|
BCG Vaccine | 1 | 2023 | 383 | 0.040 |
Why?
|
Arylamine N-Acetyltransferase | 1 | 2020 | 87 | 0.040 |
Why?
|
Metabolic Clearance Rate | 1 | 2020 | 363 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2021 | 6320 | 0.040 |
Why?
|
Pregnancy Trimester, First | 1 | 2024 | 917 | 0.040 |
Why?
|
Alanine | 1 | 2021 | 614 | 0.040 |
Why?
|
Liver Function Tests | 1 | 2019 | 526 | 0.040 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2020 | 622 | 0.040 |
Why?
|
Infant, Very Low Birth Weight | 1 | 2019 | 409 | 0.030 |
Why?
|
HIV Antibodies | 1 | 2023 | 1341 | 0.030 |
Why?
|
Drug Interactions | 1 | 2020 | 1418 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2020 | 12467 | 0.030 |
Why?
|
Administration, Topical | 1 | 2017 | 704 | 0.030 |
Why?
|
Infant Mortality | 1 | 2019 | 754 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2023 | 2009 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2727 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2021 | 3163 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2017 | 1586 | 0.030 |
Why?
|
Biopsy | 1 | 2024 | 6805 | 0.030 |
Why?
|
Ultrasonography, Prenatal | 1 | 2021 | 1771 | 0.030 |
Why?
|
Gestational Age | 1 | 2021 | 3621 | 0.020 |
Why?
|
Drug Resistance, Viral | 1 | 2017 | 869 | 0.020 |
Why?
|
Adolescent | 4 | 2021 | 89244 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4862 | 0.020 |
Why?
|
Child | 3 | 2023 | 80960 | 0.020 |
Why?
|
Body Weight | 1 | 2020 | 4628 | 0.020 |
Why?
|
Administration, Oral | 1 | 2017 | 4040 | 0.020 |
Why?
|
Medication Adherence | 1 | 2019 | 2192 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2023 | 9264 | 0.020 |
Why?
|
Genotype | 1 | 2020 | 13048 | 0.020 |
Why?
|
Prevalence | 1 | 2023 | 15879 | 0.020 |
Why?
|
Prospective Studies | 2 | 2020 | 54962 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2024 | 65480 | 0.010 |
Why?
|
Health Care Costs | 1 | 2017 | 3270 | 0.010 |
Why?
|
Male | 4 | 2023 | 365203 | 0.010 |
Why?
|
Middle Aged | 3 | 2024 | 223737 | 0.010 |
Why?
|
United States | 1 | 2023 | 73186 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2017 | 59739 | 0.010 |
Why?
|
Aged | 1 | 2017 | 171786 | 0.000 |
Why?
|